This week, the Institute of Technology in Immunobiologicals (Bio-Manguinhos) plans to release 2 million doses of the vaccine against covid-19. Between April 12 and 17, an additional 5 million will be made available to the Ministry of Health. In the following weeks, 4.7 million will be delivered, from April 19 to 24; and 6.7 million, from April 26 to May 1.
The Fiocruz schedule predicts that 100.4 million doses will be produced in Bio-Manguinhos by July, using an active pharmaceutical ingredient (IFA) imported from China.
Until April 2, 4.1 million doses were produced in Brazil and delivered to the Ministry of Health, and another 4 million were imported ready-made from India, where they were manufactured by the Serum Institute.
The last delivery made by Fiocruz to the PNI was made last Friday, when 1.3 million doses were released for distribution to states and municipalities.
Fiocruz even predicted that it would release 27 million doses in April, but revised this schedule and reduced the forecast to 18.8 million. According to a statement released by the foundation, “because it is a new technology and the complexity of implementing the production of the covid-19 vaccine, adjustments to the schedule were necessary”.
The production of the vaccine in Bio-Manguinhos takes place thanks to a technological order contract signed last year with the developers of the vaccine: the Anglo-Swedish pharmaceutical company AstraZeneca and the University of Oxford, in the United Kingdom.
Fiocruz expects to deliver 21.5 million doses in May, 34.2 million in June and 22 million in July. To produce these vaccines, Bio-Manguinhos relies on the arrival of IFA shipments from China. So far, there are already enough inputs in Brazil for the production of 35 million doses, which covers production until May.
The last batch of IFA, with the necessary to produce 5.3 million doses, landed last week in Brazil. In April, three more consignments of the input are expected to be imported. In May, four shipments are scheduled, and the last batch will arrive in June.
Fiocruz is also working to incorporate IFA’s production technology into the Bio-Manguinhos industrial plant and predicts that, in the second half, it will be possible to deliver 110 million doses from active pharmaceutical ingredients produced at the institution itself. Thus, the National Immunization Program should receive, by the end of the year, 210.4 million doses of the Oxford / AstraZeneca vaccine produced in Brazil, in addition to 12 million doses imported from India.
The Oxford / AstraZeneca vaccine has an application schedule that provides for two doses per person, with a recommended interval of 12 weeks. According to clinical studies carried out by the developers, the vaccine has an efficacy of 76% already in the first dose, 22 days after application. With the second dose, administered about three months after the first, the effectiveness rises to 82%. Protection against severe forms of covid-19 is 100%.
Get the latest news delivered to your inbox
Follow us on social media networks